ALLR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	186 170
Gjennomsnittsvolum	517 917
Markedsverdi	687 914
EPS	$0 ( 2024-03-08 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0140 (0.94%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-01	Benjamin Laura	Buy	0
2023-08-01	Vazzano Joseph Walter	Buy	0
2021-12-20	Carchedi Steve	Sell	70 477	Stock Options
2021-12-20	Carchedi Steve	Sell	156 025	Stock Options
2021-12-20	Carchedi Steve	Sell	252 555	Stock Options

INSIDER POWER
0.00
Last 5 transactions
Buy: 0 \| Sell: 505 299

Volum Korrelasjon

Lang: 0.28 (neutral)

Kort: -0.69 (moderate negative)

Signal:(51.285) Neutral

Allarity Therapeutics, Korrelasjon

10 Mest positive korrelasjoner
JBLU	0.983
AKTS	0.982
FGEN	0.98
BIOL	0.979
NVCR	0.977
WOOF	0.976
SNPX	0.975
RIDE	0.974
HCSG	0.973
GSIT	0.973

10 Mest negative korrelasjoner
MSDA	-0.984
BRIVU	-0.984
NVCN	-0.973
BRIV	-0.972
SGII	-0.971
VLAT	-0.969
TIOA	-0.966
IXAQ	-0.963
TIOAU	-0.962
ALOR	-0.961

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Allarity Therapeutics, Korrelasjon - Valuta/Råvare

-0.32
( neutral )

-0.36
( neutral )

0.00
( neutral )

-0.36
( neutral )

0.00
( neutral )

0.26
( neutral )

Allarity Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-37 000.00 (0.00 %)
EPS:	$-119.56

FY	2023
Omsetning:	$0
Bruttogevinst:	$-37 000.00 (0.00 %)
EPS:	$-119.56

FY	2022
Omsetning:	$0
Bruttogevinst:	$-120 000 (0.00 %)
EPS:	$-2 359.71

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.630

Financial Reports:

No articles found.

Allarity Therapeutics,

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.